Source comparison
BPC-157 and Shin Splints: Treatment Comparison
BPC-157 (250–500mcg daily) Upregulates VEGFR-2 and fibroblast activity; accelerates periosteal collagen synthesis and angiogenesis 4–6 weeks (Grade 1–2); 6–8 weeks (Grade 3) $50–$100 for 4–6 week supply Animal studies and case reports; no human RCTs Mechanisti
This comparison does not assign a generated winner or score.
- BPC-157 (250–500mcg daily)
- Upregulates VEGFR-2 and fibroblast activity; accelerates periosteal collagen synthesis and angiogenesis
- 4–6 weeks (Grade 1–2); 6–8 weeks (Grade 3)
- $50–$100 for 4–6 week supply
- Animal studies and case reports; no human RCTs
- Mechanistically plausible for periosteal repair; requires concurrent training modification; not FDA-approved for human use
- Rest + Ice + NSAIDs (standard care)
- Reduces inflammation; allows natural healing through mechanical offloading
- 6–8 weeks (Grade 1–2); 8–12 weeks (Grade 3)
- $10–$30 (over-the-counter NSAIDs)
- Consensus-based guideline; no controlled trials for NSAIDs in MTSS
- Gold standard conservative approach; works but slow; NSAIDs may impair bone remodeling if used long-term
- Platelet-Rich Plasma (PRP) injection
- Delivers autologous growth factors (PDGF, TGF-β, VEGF) to injury site
- 4–6 weeks (single injection); may require 2–3 sessions
- $500–$1,500 per injection
- Limited human studies in MTSS; stronger evidence in tendon injuries
- Clinically administered; FDA-cleared for some orthopedic uses; more expensive but more consistent published outcomes than BPC-157
- Extracorporeal Shockwave Therapy (ESWT)
- Mechanical stimulation induces neovascularization and tissue remodeling
- 3–6 sessions over 6 weeks; improvement at 8–12 weeks
- $1,500–$3,000 for full treatment series
- Moderate-quality evidence (small RCTs); effective for chronic cases
- Non-invasive; works for refractory cases that don't respond to rest; expensive and requires clinical access